Procon plus

The Procont dietary supplement capsule contains an immunoactive active ingredient derived from a biological system extracted with technology protected by an international patent, and has a general antitumor effect. It exerts its effect during the phase of cell division, namely through the tumor suppressor gene: maintaining its physiological level, it recognizes transcription errors in the process of cell division and immediately destroys the cell that has not yet divided into two. The owner of the patent behind the active ingredient is Dr. András Bertha, an experimental toxicologist and pharmacist-pharmacologist. The patent is international patent P0200172 January 2003. On the 15th, he received the number PCT/HU0300004.

Based on the preclinical tests, we can state that the active ingredient:
– its survival rate is several times higher than that of active substances known today,
– based on the tumor types examined so far, it is not cancer-specific,
- no toxic side effects even with a 50-fold overdose,
– the distance between therapeutic and toxic doses is large,
- it is also effective when the tumor is significantly advanced.

Advantages of the invention over other technologies:
- According to the preclinical studies performed on animals, it can be stated that it has a general antitumor effect.
– It exerts its effect during the phase of cell division, namely through the tumor suppressor gene: maintaining its physiological level, it recognizes transcription errors in the process of cell division and immediately destroys the cell that has not yet divided into two. The literature knows the key role of the tumor suppressor gene in tumor processes, but according to today's knowledge, no active substance is known that would influence the physiological level of this gene (by acting on it).
– It has no immunosuppressive effect, our measurements confirm that the status of the immune system is maintained.
- It has a wide therapeutic range.
"It's not toxic."
- Its harmful side effects are not known.
– It can be produced from a biological system, the raw material source is widely available.

Description of the results of the experiments:
In each tumor type, the average survival time of the positive control group is 100%, to which we compare the survival time of the treated groups. The therapeutic threshold value of chemotherapy agents included in today's medicines must be at least 125%. The higher this value, the more certain the therapeutic effectiveness.

Based on our current results, the following can be stated about the biologically active active ingredient based on animal experiments:
– In acute lymphoid leukemia, the average survival time of animals is 320%.
– Even in S-180 sarcoma, the average survival time of the animals (BDF1 male mice) significantly exceeded that of the positive control group (100%) (280%). The average mass of the tumors decreased to about 1/3. The frequency of metastases was drastically reduced as a result of ABB-7 treatment compared to the positive control group. This is supported by histology, enzymatic tumor markers and laboratory diagnostic measurements.
– In the case of C26 colon tumors, the average survival time of the animals was 220% and the average weight of the tumors was reduced by less than half.
– For MXT breast carcinoma, survival is 149%. The average tumor weight was reduced by 1/4. (BDF1 in female mice)

Recommended consumption:
3 capsules per day, but in any case consult your doctor regarding the exact dosage. Do not consume more than the recommended amount of the product. The consumption of dietary supplement products does not replace a varied and correct diet.

The consumption of the product is recommended in the following cases:
– For all types of cancer, as the active ingredient of Procont is not tumor-specific.
– For prevention, if a certain type of (genetically confirmed) tumor process accumulated in the family can be traced.
– Note: Procont product (since it is not a medicine) can NOT be used as an exclusive treatment, only as an additional treatment in addition to traditional oncotherapeutic procedures (if cancer treatments can no longer be used for someone, the Procont preparation can be given with a doctor's opinion).